Press releaseGlobe Newswire
Perceptive Capital Solutions
FRNM · NASDAQ
$12.77−$0.33 (−2.52%)TodayMarket closed ·
Prev close $13.10
Latest news
- Press releaseGlobe Newswire
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
- NewsChandrima Sanyal
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
- NewsAvi Kapoor
Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday
- Press releaseGlobe Newswire
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
- Press releaseGlobe Newswire
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
- Press releaseGlobe Newswire
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.